Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie : Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP [Therapeutic drug monitoring in neuropsychopharmacology : Summary of the consensus guidelines 2017 of the TDM task force of the AGNP]
- Unterecker, Stefan
- Hefner, Gudrun
- Baumann, Pierre
- Gründer, Gerd
- Bergemann, Niels
- Clement, Hans Willi
- Conca, Andreas
- Deckert, Jürgen
- Domschke, Katharina
- Eckermann, Gabriel
- Egberts, Karin
- Gerlach, Manfred
- Greiner, Christine
- Haen, Ekkehard
- Havemann-Reinecke, Ursula
- Helmer, Renate
- Janssen, Ger
- Jaquenoud, Eveline
- Laux, Gerd
- Messer, Thomas
- Mössner, Rainald
- Müller, Matthias J.
- Paulzen, Michael
- Pfuhlmann, Bruno
- Riederer, Peter
- Saria, Alois
- Schoppek, Bernd
- Schoretsanitis, Georgios
- Schwarz, Markus
- Gracia, Margareta S.
- Stegmann, Benedikt
- Steimer, Werner
- Stingl, Julia C.
- Uhr, Manfred
- Ulrich, Sven
- Waschgler, Rroland
- Zernig, Gerald
- Zurek, Gabrieal
- Hiemke, Cchristoph
Publication date
May 2019
DOIAbstract
Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood serum or plasma to optimize pharmacological therapy. TDM is an instrument with which the high interindividual variability of pharmacokinetics of patients can be identified and therefore enables a personalized pharmacotherapy. In September 2017 the TDM task force of the Working Group for Neuropsychopharmacology and Pharmacopsychiatry (AGNP) published an update of the consensus guidelines on TDM published in 2011. This article summarizes the essential statements for the clinical practice in psychiatry and neurology
Add to ORKG